Parameter

Dosing Condition

Fasting

Fed

Low-fat meal*

Medium-fat meal

High-fat meal

Cmax (ng/ml)

433 ± 111 (26)
[419]

471 ± 117 (25)
[455]

463 ± 118 (26)
[447]

500 ± 121 (24)
[483]

tmax (h)†

6.00 (4.00, 24.00)

10.00 (4.00, 16.00)

8.00 (4.00, 16.00)

8.00 (6.00, 12.00)

t½ (h)

10.73 ± 1.69 (16)
[10.60]‡

10.64 ± 1.74 (16)
[10.49]

11.04 ± 4.68 (42)
[10.53]

10.39 ± 2.13 (21)
[10.18]

AUCT (ng*h/ml)

11019 ± 2863 (26)
[10541]‡

10797 ± 2496 (23)
[10434]

11200 ± 2346 (21)
[10907]

10507 ± 2609 (25)
[10096]

AUC (ng*h/ml)

11245 ± 2936 (26)
[10759]‡

10995 ± 2558 (23)
[10624]

11496 ± 2562 (22)
[11170]

10683 ± 2703 (25)
[10259]

Cl/F (L/h)

19.90 ± 9.91 (50)
[18.59]‡

19.81 ± 8.32 (42)
[18.83]

18.6 ± 6.38 (34)
[17.90]

20.68 ± 9.18 (44)
[19.50]

Cl/F (L/h/kg)

0.27 ± 0.14 (50)
[0.25]‡

0.27 ± 0.10 (39)
[0.25]

0.26 ± 0.08 (31)
[0.25]

0.28 ± 0.12 (43)
[0.26]

AUC: Area Under the Concentration-Versus-Time Curve; AUCT: AUC to the Last Quantifiable Concentration at Time T; Cl/F: Apparent Oral-dose Clearance; Cmax: Peak Plasma Concentration; CV: Coefficient of Variation; t½: Apparent Terminal-phase Elimination Half-life; tmax: Time to Cmax.
*One subject in the low-fat treatment group was excluded. †Median (minimum, maximum) for tmax. ‡One subject in the fasting treatment group was excluded.
Table 1: Plasma Pharmacokinetic Parameters Following a Single, Oral, 200 mg Dose of Desvenlafaxine Administered Under Fasting and Fed Dosing Conditions; Mean ± SD (CV%), [Geometric Mean].
Goto home»